Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | +24.77% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.82 | N/A | +24.77% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions and indicated a cautious approach. They did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
Kodiak Sciences reported a wider-than-expected loss per share, which was a positive surprise compared to previous expectations. However, the lack of revenue data and guidance contributed to a negative stock reaction, with shares dropping 2.6%. Investors may be concerned about the company's future performance given the current market challenges highlighted by management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
D-WAVE QUANTUM INC
May 13, 2024